Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 Annual Meeting

LEXINGTON, Mass.--()--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced three poster presentations at the American Glaucoma Society 2017 Annual Meeting to be held March 2-5 in Coronado, CA. The presentation details are as follows:

  • Incidence of Hyperemia in the Trabodenoson Monotherapy Clinical Development Program Through Phase 2
    Poster #: 87
    Authors: C Rich, LJ Katz, C Murray, N Dgetluck, and R Baumgartner
    Date: Friday, March 3, 2017
    Time: 7:00am to 8:00am PST
  • Improved Function of Retinal Ganglion Cells by Topically Administered Trabodenoson in a Rat Model of Optic Nerve Crush Injury
    Poster #: 96
    Authors: A Brockman, D Albers, J Tsai, C Rich, R Baumgartner, and W McVicar
    Date: Friday, March 3, 2017
    Time: 7:00am to 8:00am PST
  • Further Elucidation of the Mechanism of Action of Trabodenoson Using Validated 3D-Human Trabecular Meshwork Constructs
    Poster #: 140
    Authors: D Albers, R Noecker, A Unser, F Ahmed, K Torrejon, R Baumgartner, and W McVicar
    Date: Saturday, March 4, 2017
    Time: 7:00am to 8:00am PST

Inotek will have an exhibition booth set up at #T27.

About Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com. The inclusion of our website address here and elsewhere in this press release does not include or incorporate by reference the information on our website into this press release.

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Inotek Contact:
Claudine Prowse, PhD, 781-552-4305
Vice President, Corporate Development and IRO
IR@inotekpharma.com

Release Summary

Inotek Pharmaceuticals Corporation today announced three poster presentations at the American Glaucoma Society 2017 Annual Meeting to be held March 2-5 in Coronado, CA.

Contacts

Inotek Contact:
Claudine Prowse, PhD, 781-552-4305
Vice President, Corporate Development and IRO
IR@inotekpharma.com